Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Using data from six population-scale cohorts involving more than 10 million individuals, a large language model-based aging signature is shown to outperform traditional aging biomarker indices and signatures in predicting multiple health outcomes, at general and organ-specific levels.
In a phase 1b trial in three patients with Fanconi anemia, an irradiation- and busulfan-free conditioning regimen containing an anti-CD117 antibody, combined with T cell- and B cell-depleted haploidentical hematopoietic stem cell transplantation, was safe and led to high levels of donor engraftment.
A combination of animal studies, data from a clinical trial and insights from an observational cohort suggest that, in individuals with metabolic dysfunction-associated steatohepatitis, semaglutide improves liver histology by reverting patient proteomes to better mimic the proteome of individuals without the disease.
Polygenic scores for body mass index and obesity constructed using data from 5 million people with different ancestries were associated with distinct weight gain trajectories from early childhood to adulthood.
By systematic analysis of patient cases, we evaluated the clinical utility of open-source large language models (LLMs), such as the DeepSeek models, for implementation in medical applications. Their performance on clinical decision-making tasks was comparable to and partly better than proprietary models GPT-4o and Gemini-2.0 Flash Thinking Experimental, respectively.
To facilitate the safe and effective implementation of autonomous artificial intelligence agents in healthcare, regulatory frameworks must evolve beyond static device paradigms to incorporate adaptive oversight and flexible pathways.
In a prospective study including 2,300 pediatric and adult patients with liquid and solid tumors, RNA sequencing provided actionable molecular information in 87% of cases, with applications in diagnostics and therapy matching.
This Review summarizes the current knowledge on mortality-defining toxicities of chimeric antigen receptor T cell therapies beyond cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome. The authors discuss underlying mechanisms and how these affect timing and management, and outline key unmet needs and future priorities.
In this multicenter phase 1 trial, treatment with IBI343, a CLDN18.2-targeting antibody–drug conjugate, was safe and showed encouraging clinical responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
In this multicenter phase 1 trial, patients with advanced gastric and gastroesophageal junction cancer were safely treated with the CLDN18.2-targeting antibody–drug conjugate SHR-A1904, leading to encouraging objective response rates.
A new Global Neurodegeneration Proteomics Consortium provides a wealth of data to boost mechanistic understanding, biomarker research and drug development during aging and in neurodegenerative diseases — and dementia in particular.
Over 11,000 plasma and cerebrospinal fluid proteomic samples reveal that the APOE ε4 genetic variant is associated with a systemic pro-inflammatory signature in a variety of neurodegenerative diseases.
Deep phenotyping of an ancestrally diverse group of 13,000 individuals in the Human Phenotype Project highlights diversity and variations in lifestyle factors, clinical features and molecular signatures of health and disease.
